secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-09-30T12:30:29+00:00
Accession:  0001493152-26-045034
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

bioAffinity debuts CyPath Lung with AvMEDICAL at NAVREF conference to 300+ VA physicians
--------------------------------------------------------------------------------

- bioAffinity and AvMEDICAL, a Service-Disabled Veteran-Owned Small Business, held the first joint CyPath Lung exhibition at NAVREF 2026 in Arlington, Virginia, reaching 300+ attendees.
- The VA reports about 7,700 veterans are diagnosed with lung cancer each year; the federal distribution agreement aims to expand veteran access to the noninvasive test.
- CyPath Lung showed 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in a published trial of high-risk patients with nodules under 20 mm.
- bioAffinity also presented CyPath Lung at the GO2 for Lung Cancer Centers of Excellence conference in San Diego; GO2 works with the VA and 700+ screening centers.
- The nationwide agreement uses AvMEDICAL's government contracting expertise and procurement channels; AvMEDICAL has more than doubled its product portfolio since 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226045034/0001493152-26-045034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226045034/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-045034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer